Posted by admin on Jun 22nd, 2022
Bausch + Lomb (NYSE:BLCO – Get Rating) and Warby Parker (NYSE:WRBY – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.
This table compares Bausch + Lomb and Warby Parker’s net margins, return on equity and return on assets.
This table compares Bausch + Lomb and Warby Parker’s gross revenue, earnings per share and valuation.
Bausch + Lomb has higher revenue and earnings than Warby Parker.
This is a breakdown of recent ratings and target prices for Bausch + Lomb and Warby Parker, as provided by MarketBeat.
Bausch + Lomb presently has a consensus price target of $23.33, suggesting a potential upside of 50.54%. Warby Parker has a consensus price target of $32.20, suggesting a potential upside of 140.48%. Given Warby Parker’s higher probable upside, analysts plainly believe Warby Parker is more favorable than Bausch + Lomb.
98.6% of Warby Parker shares are owned by institutional investors. 25.4% of Warby Parker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
About Bausch + Lomb (Get Rating)
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
About Warby Parker (Get Rating)
Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. The company also offers eye exams and vision tests directly to consumers through its retail stores, website, and mobile apps. As of May 16, 2022, it had 160 retail stores in the United States and Canada. The company was formerly known as JAND, Inc. and changed its name to Warby Parker Inc. in June 2021. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
Head to Head Comparison: Hormel Foods (NYSE:HRL) & Bit Origin (NASDAQ:BTOG)
Peyto Exploration & Development Corp. (OTCMKTS:PEYUF) Announces $0.04 Dividend